Sacubitril/valsartan (LCZ696)

製品コードS7678 バッチS767803

印刷

化学情報

Chemical Structure Synonyms Sacubitril, Valsartan Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C24H29N5O3.C24H29NO5.5/2H2O.3Na
分子量 915.98 CAS No. 936623-90-4
Solubility (25°C)* 体外 DMSO (warmed with 50ºC water bath) 100 mg/mL (109.17 mM)
Water (warmed with 50ºC water bath) 100 mg/mL (109.17 mM)
Ethanol (warmed with 50ºC water bath) 100 mg/mL (109.17 mM)
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
in vivo In double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity, Sacubitril/valsartan (LCZ696) (60 mg/kg p.o.) induces a dose-dependent and long-lasting reduction in mean arterial pressure (MAP), and stimulates a rapid and dose-dependent augmentation of plasma ANP immunoreactivity. [1] In rat myocardial infarction (MI) model, this compound (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. [2]

プロトコル(参考用のみ)

動物実験 動物モデル Double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity
投薬量 ~60 mg/kg
投与方法 p.o.

参考

  • https://pubmed.ncbi.nlm.nih.gov/19934029/
  • https://pubmed.ncbi.nlm.nih.gov/25362207/

カスタマーフィードバック

Data from [Data independently produced by , , J Mol Cell Cardiol, 2017, 108:138-148]

Data from [Data independently produced by , , RSC Adv, 2017, doi:10.1039/C7RA01404J]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Computational drug repurposing in Parkinson's disease: Omaveloxolone and cyproheptadine as promising therapeutic candidates [ Front Pharmacol, 2025, 16:1539032] PubMed: 40264664
Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [ J Immunother Cancer, 2024, 12(11)e009805] PubMed: 39581704
LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates epithelial-mesenchymal transition of peritoneal mesothelial cells and M2 macrophage polarization [ Ren Fail, 2024, 46(2):2392849] PubMed: 39165231
LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4 [ Biomed Pharmacother, 2023, 162:114569] PubMed: 37001183
Sacubitril/valsartan alleviates sepsis-induced acute lung injury via inhibiting GSDMD-dependent macrophage pyroptosis in mice [ FEBS J, 2023, 290(8):2180-2198] PubMed: 36471663
Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis [ Oxid Med Cell Longev, 2022, 2022:5009289] PubMed: 36193085
Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis [ Oxid Med Cell Longev, 2022, 2022:5009289] PubMed: 36193085
Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity [ Arch Toxicol, 2022, 96(4):1065-1074] PubMed: 35152301
Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction [ ESC Heart Fail, 2022, 10.1002/ehf2.14186] PubMed: 36303443
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension [ Cardiovasc Res, 2021, 117(5):1391-1401] PubMed: 32653925

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。